Summary Flunarizine is a class IV calcium channel blocker which increases oxygen delivery to hypoxic regions in solid tumours, exerting a radiosensitising effect in vivo in animal tumour models. Precisely how the drug improves oxygenation is not well understood. We hypothesised that metabolic conditions present within solid tumours reduce red blood cell (RBC) deformability and that flunarizine exerts its in vivo effect by preventing this loss of RBC deformability. A al., 1991). Blood flow in tumour microvasculature involves complex interactions of cellular elements, variable pressure gradients, and irregular vessel morphology (Jain, 1988) . However, in very small vessels and capillaries, the deformability of the individual erythrocyte (RBC) becomes increasingly more important as the discoid cell must fold over onto itself in order to navigate through passageways often smaller than its own diameter. Indeed, there exists direct evidence of the impact of altered RBC deformability on the apparent in vivo blood viscosity in tumour microcirculation. For example, Sevick and Jain have used hyperglycemia to induce slight cell volume changes which impair RBC deformability, thus causing measurable increases in the pressure gradient required for equivalent flow rates across tumour vascular beds (1991).
Attempts have been made to use a variety of blood flow modifiers in an effort to improve oxygen delivery to hypoxic regions of tumours, thereby enhancing radiosensitivity (Horsman et al., 1991) . Blood flow in tumour microvasculature involves complex interactions of cellular elements, variable pressure gradients, and irregular vessel morphology (Jain, 1988) . However, in very small vessels and capillaries, the deformability of the individual erythrocyte (RBC) becomes increasingly more important as the discoid cell must fold over onto itself in order to navigate through passageways often smaller than its own diameter. Indeed, there exists direct evidence of the impact of altered RBC deformability on the apparent in vivo blood viscosity in tumour microcirculation. For example, Sevick and Jain have used hyperglycemia to induce slight cell volume changes which impair RBC deformability, thus causing measurable increases in the pressure gradient required for equivalent flow rates across tumour vascular beds (1991) .
An agent capable of improving the deformability of RBC's might be useful in the enhancement of radiosensitivity if there is reason to believe that loss of deformability selectively occurs within the environment of the tumour, thus compromising blood flow and oxygen delivery there. Prominent characteristics of tumour centres include significant hypoxia and the lactic acidosis which may result in such circumstances (Vaupel et al., 1989) , and it has recently been confirmed by direct measurement that PO2 within flowing tumour vessels may be lower than 10 mmHg (Dewhirst et al., 1992a) . It was our specific intention to determine whether such environmental conditions adversely affect the deformability of erythrocytes. Also, it was our goal to assess whether flunarizine has activity in these conditions in reversing any loss of RBC deformability.
Flunarizine (E-1 -[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride) is a WHO class IV calcium-entry blocking agent which enhances radiosensitivity in vivo in animal models (Wood & Hirst, 1988) . Numerous studies have demonstrated that the drug significantly improved blood flow and oxygenation in the hypoxic regions of tumours implanted experimentally in animals (Kaelin et al., 1984; Vaupel & Menke, 1987; Fenton & Sutherland, 1992) . Since this effect was not associated in our most recent studies with changes in tumour vessel pressure gradients, diameters, density, or morphology (Dewhirst et al., 1992b) , we have hypothesised that the drug exerts an effect on the viscosity of blood flowing through tumour microvasculature.
In order to investigate the rheological properties of RBC's in controlled conditions of low P02, low pH, and excess lactate concentration which simulate the in vivo milieu of hypoxic tissues, a closed chamber microrheometer (Tran-SonTay et al., 1988) For treatment in conditions of low pH, the relative proportions of Hepes acid and Hepes buffer salt were adjusted to yield solutions of pH 6.8 (range 6.67-6.85). Exposure to lactate was achieved by dissolving a sufficient quantity of sodium lactate (Sigma, St. Louis, MO) in HBS of pH 7.4 or 6.8 in order to obtain lactate concentrations of 5 mMol l-, maintaining osmolarity between 290-300 mOsm`'. Flunarizine (Janssen Pharmaceuticals, Beerse, Belgium) was added from stock aqueous solutions of concentration 0.5 or 1.0 mg ml-'. The solutions were prepared by dissolving 5-10 mg of flunarizine into 1.0 ml of filtered 95% aqueous ethanol to which 9.0 ml of de-ionised water was then added. The mixture was vortexed for 10 min to enhance entry into solution. With a digital pipettor, the flunarizine solution was added to the HBS of pH 7.4 or the low pH lactate solutions in order to achieve concentrations of 5, 10, or 50 mg I'; iso-osmolar conditions were maintained by adding de-ionised water or sodium chloride as needed.
After exposure to HBS at pH 7.4 (normal control) or to the adjusted experimental solution for 20-30 min, the 10% hematocrit suspensions were centrifuged for 20 min at 1700 r.p.m. at 1 5°C. A sufficient amount of supernatant was removed to yield a hematrocrit of 90%. The final hematocrit was checked by capillary tube centrifugation. Values from 88-92% were considered acceptable for testing. Suspensions outside the range 88-92% were adjusted either by adding back a small amount of the removed supernatant or repeating the centrifugation and removing additional supernatant.
De-oxygenation
Hypoxia was achieved by exposing the 90% hematocrit suspensions to a humidified 95% N2/5% CO2 gas mixture. The pH of the suspension was not altered by this treatment. After preparation as described above, 0.5-1.0 ml of the erythrocyte suspension was collected into a 1.0 ml syringe and injected into a 25-30 cm length of 0.635 cm ID Silastic (Dow Corning, Midland, MI) tubing which was suspended along the inner walls of a 30 x 30 x 40 cm Lucite.m glove box. The hinged box top was sealed airtight with vacuum grease and clamped. The N2/CO2 mixture was humidified by bubbling through two water-containing beakers before being introduced into the glove box via an inlet valve. After 20 min continuous flow through the 1.0 cm diameter inlet valve at 8-1O psi, a PO2 of less than 3 mmHg inside the box was obtained. Exposure of the suspensions to the hypoxic gas mixture for 90 min yielded blood PO2 of less than 10 mmHg. Gas and blood PO2 levels were verified with a blood gas analyser (Model ABL 30, Radiometer, Copenhagen). The suspensions of RBC's were easily recovered from the Silastic tubing by aspiration back into the syringe.
Density profile measurements
Small aliquots (50 -100 Ll) of the erythrocyte suspensions were injected into two capillary tubes to which a droplet of phthalate ester oils of known density (either 1.095 or 1.105 g ml-') was added. The cells were then centrifuged at 13,450 g for 3 min (IEC model MB, Needham Heights, MA). Following centrifugation the cells were apportioned into three compartments. 'Low density' cells were less dense than the lighter oil (< 1.095 g ml-'), and 'high density' cells were more dense than the heavier oil (>1.105 g ml-'). The remaining cells were of intermediate density (1.095-1.105 g ml-').
Microrheometer A magneto-acoustic ball microrheometer was used to perform viscosity measurements in a manner previously described in detail (Tran-Son-Tay et al., 1988 and 1989 Bessis (1973) . The alteration from the normal discoid morphology results from the release of portions of the membrane at the centre of the disc from points at which they are tethered to the inner cytoskeleton of cytoplasmic proteins, thus leaving only one-sided invagination of the membrane that yields the cupped shape. The cells are readily identified by light microscopy, and the proportion of stomatocytes among the total population of RBC's is easily scored. In rat blood qualitatively similar trends were observed in most instances, as seen in Figure 1, Combined effects of hypoxia, excess lactate, and low pH and response to varying concentrations offlunarizine Illustrated in Figure 2 are the absolute viscosities of suspensions of RBC's pre-treated with flunarizine in concentrations of 5, 10, and 50 mg 1-1 prior to exposure to hypoxia, low pH, and lactate. In humans, relative to the viscosity measured under these conditions without drug, treatment with flunarizine produced a decrease in viscosity at all concentration levels (P = 0.06, 0.02, and 0.06, respectively for 5, 10, and 50 mgI 1). The magnitude of the change observed at 1Omg' 1 ranged from 8% to 46%. In rat blood the results were qualitatively similar except at the highest dose level, where viscosity rose back to values equal to those obtained in the combination of hypoxia, low pH, and lactate. Viscosity was significantly increased at a concentration of 50 mg 1' compared to the nadir observed at 5 and 10 mg 1' (P<0.05).
Statistics
Density profile studies Changes in the cell density distribution generall paralleled changes in viscosity measurements, with shifts toward decreased cell density accompanying decreases in suspension viscosity. In Figure 3 are the human red cell density profiles observed after exposure to flunarizine (10 mg 1-), low pH, hypoxia, and excess lactate concentration, with the average normal ( Figure 3 . When RBC's were pre-treated with flunarizine prior to exposure to hypoxia, low pH, and lactate, a dose-dependent shift toward lower cell density was observed (Figure 4) . The increase in the low density fraction (<1.095 mg 1') was significant for all concentrations in human cells (P = 0.02, 0.03, and <0.01 for 5, 10, and 50mg I`). Again, the same pattern of response was detected in the rat red cells. The percentages of high density cells decreased from the untreated state for all concentrations (P<0.05).
Morphology studies
After exposure to low (10 mg 1') or high (50 mg Il) concentrations of flunarizine, the most obvious shape change seen was an increase in the number of stomatocytes, in both rat and human blood (Figures 5a,b) . The percent of stomatocytes observed rose from 12 + / -2% in control conditions to 26 + / -8% and 68 + / -7% in human cells exposed to flunarizine in concentrations of 10 and 50 mg 1-', respectively. Similarly, the percent of stomatocytes among the rat RBC's rose from a control level of 19 + / -2% to 29 + / -5% and 48 + / -9% in the low and high concentration exposures. Compared with baseline values in the absence of flunarizine, the percentage was significantly higher for both rat and human cells at the higher concentrations (P<0.001). It was our impression that at the high dose level the rat red cells became more spherical (sphero-stomatocytic) than simply cup-shaped, although this effect could not be quantified with the techniques employed.
Discussion
The effect of hypoxia per se as a factor impacting upon RBC deformability has been debated. There have been reports supporting (Gross & Hathaway, 1972; Lacelle & Weed, 1970) and refuting (Brereton & Murphy, 1974; Hermann et al., 1981; Usami et al., 1975 ) the hypothesis that hypoxia reduces erythrocyte deformability. Also, species-to-species variability in the effect of hypoxia on RBC deformability has been reported. Rat RBC's in particular become significantly less deformable at a P02 of 50 mmHg than at P02 of 150 mmHg (Hakim & Macek, 1988) , while other non-human species are less affected. Most provocative in our opinion, though, is the observation by De that in humans flunarizine could prevent the measurable decrease in RBC filterability in venous blood obtained after regional arterial occlusion. Although P02 and pH are not reported in this initial study, it is plausible that the ischemia produced by this method in many ways models the poorly oxygenated and acidotic reigons within solid tumour cores.
Extremes of hypoxia such as those found in tumours have not been thoroughly examined. Although Koutsouris (1985) reports no change in RBC deformability even at P02 Of 0 mmHg, the technique employed involved filtration through 5 ;m pores. Alterations in RBC deformability might not be detected by filtration through pores this large, requiring in-stead smaller apertures for the cells to transit to improve the sensitivity of the test (Frank & Hochmuth, 1988) . Furthermore, Koutsouris does not evaluate possible changes in RBC density in extreme hypoxia. Frank and Hochmuth (1988) use a Percoll gradient method to separate populations of red cells according to density prior to testing deformability by a resistive pulse technique. The denser subpopulations of aged cells require significantly longer transit times through 5 and 6 jLm diameter pores because of increased resistance to shear deformation due to a reduction in membrane surface area. Osmotically shrunken cells, which are denser than normal cells because of increased intracellular hemoglobin, similarly have longer transit times through 3.6 and 5.0 gm pores as a result of increased shear viscosity of the membrane and increased viscosity of the cytoplasm. In the present studies, exposure of RBC's to PO2 below 10 mmHg causes a significant increase in cell density, which corresponds to an increase in suspension viscosity. Since iso-osmolar conditions are maintained throughout, it appears more likely that density increases under conditions of extreme hypoxia occur by a mechanism of membrane damages similar to those which occurs during cell senescence. However, the contribution to increased internal viscosity of any increase in intracellular hemoglobin concentration has not specifically been measured.
The most commonly reported effect of acidosis on red blood cells is a net stiffening, presumably related to direct effects on the mechanical properties of the membrane (e.g. Crandall et al., 1978) . However, it is also important to consider the recognised cell volume increase which accompanies lowering pH (Rand et al., 1968 ). There appears to be an optimal ratio of surface area to volume in order for the cell to fold over onto itself most easily. Both rat RBC's, with average mean cell volume (MCV) of 65 g3, and human RBC's, with average MCV of 90 j3, demonstrate decreased filterability with both osmotically induced shrinkage and swelling when compared with optimal cell geometry (Norton et al., 1981) . Thus, depending upon where they lie in relation to optimal proportions, a cell's baseline geometric dimensions can influence whether its deformability goes up or down following a slight cell volume increase such as that which can result within an acidotic environment. Our observation of decreased viscosity accompanied by reduced cell density in acidotic conditions is likely a result of more optimal cell surface area-to-volume ratio from the slight cell swelling.
Relatively little has been published concerning the isolated effect of lactate on red cell deformability. Waldenlind et al. (1988) report a significant decrease in RBC filterability at normal pH with concentrations of lactate up to 3.6mMol 1-1, physiologically high levels comparable to those encountered in circulatory shock. Their suggested explanation is a reaction occurring at the lactate receptor. If the effect were reproducible, this phenomenon would at least partially account for the observed decrease in RBC filterability when supposedly 'hypoxic' conditions are produced by intense muscular exercise in otherwise healthy individuals even if actual low PO2 has not been documented Guezennec et al., 1989) . In such circumstances, there has likely been considerable production of lactate: levels ranging from 2-10 mMol [-have been measured in venous blood even after submaximal exercise (Foxdal et al., 1990) .
Note that similar lactic acid concentrations have been measured within the interstitial fluid of implanted animal tumours (Gullino et al., 1964) . The reason for variability in our present results is not entirely clear. It has been shown that there is variability in rates of lactate metabolism among normal healthy individuals (Fishbein et at., 1988) , but investigations into this mechanism are beyond the scope of our present experiments.
Flunarizine is a catamphiphilic molecule that has particular affinity for erythrocyte and other cellular lipid membranes (Scheufler et al., 1990) . The effect of the drug on certain calcium-membrane interactions has been examined electron microscopically. Flunarizine prevents the particle aggregation, membrane aggregation, and blebbing which would otherwise occur in the presence of elevated calcium concentrations (Thomas et al., 1988) . With regard to how the drug might affect the shape of intact cell membranes, Flameng et al. (1979) have documented the efficacy of flunarizine in suppressing discocyte-echinocyte transformation in red blood cells subjected to cold temperatures. However, to our knowledge the drug's pro-stomatocytogenic properties per se have not previously been described.
There is a direct relationship between the calmodulin inhibitory properties of numerous drugs and their ability to generate 'cupped' erythrocytes or 'stomatocytes' (Nelson et al., 1983) . It is not clear precisely why such a shape change occurs. Calcium-dependent binding of calmodulin to both membrane-bound spectrin and to cytoplasmic cytoskeletal proteins occurs; however, inhibition of these reactions by calcium depletion fails to generate the same stomatocytosis induced by the calmodulin antagonist trifluoroperazine (Burns & Gratzer, 1985) . A more direct inclusion of calmodulin inhibitors within the RBC membrane has been postulated, consistent with the correlation of membrane fluidisation and stomatocytosis as induced by several qualitatively different methods (Noji et al., 1982) . Flunarizine inhibits calmodulin in vitro at a concentration of 4 jiM, equal to approximately 2 mg I' (Lugnier et al., 1984) . In our experiments the stomatocytogenic effect similarly suggests a primary biochemical mechanism related to the characteristics of a calmodulin' inhibitor.
Shape changes may influence RBC deformability in a variety of circumstances. Chlorpromazine, a stomatocytogenic agent, prevents the echinocytic transformation generated by ATP deletion. In a dose-dependent manner, the drug not only prevents morphologic alteration, but also inhibits the decrease in red cell suspension viscosity (measured by coneplate and oscillatory viscometers) produced by the echinocytic transformation (Meiselman, 1981; Yardin & Meiselman, 1989) . Noji et al. use several different stomatocytogenic calmodulin inhibitors to prevent loss of erythrocyte deformability induced by ionophore-stimulated intracellular calcium overload (Noji et al., 1987) . Clark et al. (1981) have suggested that ATP depletion causes impaired deformability by indirectly leading to membrane damage while calcium infusion produces the same effect by increasing the cell's internal viscosity by osmotic changes; nevertheless, treatment with stomatocytogenic agents appears to counteract the impairment of deformability under either circumstance.
Besides morphological descriptors of shape changes, a more quantitative way to characterise the effect of flunarizine upon red blood cells is in terms of how the densities of a population are changed after exposure to the drug. In the present experiments, the viscosity of the RBC suspensions was typically increased after exposure to conditions which increased the proportion of cells of higher density, which are known to be less deformable (Frank & Hochmuth, 1988 ). As noted above, the higher density likely results from membrane damage and surface area loss, possibly accompanied by net loss of internal cell volume and consequent elevation of intracellular hemoglobin. In the environment of hypoxia and lactic acidosis, this change is prevented in human and rat cells by flunarizine, which shifts cells into lower density fractions. Effectively, the drug reconstitutes optimal cell geometry, restoring the membrane and/or reducing cytoplasmic viscosity by causing slight cell swelling, thereby reducing the hemoglobin concentration.
In the rat cells, however, the reduction in viscosity is lost at high concentrations of flunarizine (50mgl1'). This is an important point in relation to the observed pattern of doseresponse noted in measures of tumour blood flow and radiosensitivity. Wood and Hirst (1989) have reported that optimal radiosensitisation in implanted murine tumours occurs at a dose of 5 mg kg-' administered intraperitoneally, with the effect lessening at higher doses up to 500 mg kg-'.
Even the initial work at this university with intravenously administered flunarizine suggests a somewhat similar biphasic response pattern of increased blood flow to tumours at optimal dosage (1 mg kg-') which diminished at a higher dose (5 mg kg-') (Kaelin et al., 1984) . Notice the two different routes of administration are used in these studies and that the former experiment was in mice and the latter in rats. Increases in potency on the order of 6-8 times have been described for other calcium channel blockers when comparing i.v. administration with oral or i.p. (Stone et al., 1980) . Pharmacokinetic studies in humans receiving oral flunarizine have suggested that flunarizine similarly undergoes significant first pass hepatic metabolism (Heykants et al., 1979) .
In consideration of such observations, we can interpret the findings of our present studies in order to account for the selective improvement in regional blood flow offered by flunarizine within hypoxic tumour cores. In local conditions of hypoxia and lactic acidosis, there can be an increase in RBC density which decreases deformability of individual cells and thus increases the effective blood viscosity in the area.
Flunarizine in low doses (5-OmgI 1) protects against such changes in both rat and human red cells. As the concentration of the drug is further increased, it appears that actual cell swelling is induced in a dose dependent manner, as evidenced by progressively reduced cell density. Human RBC's tolerate flunarizine doses at least up to a concentration of 50 mg 1-' without excessive cell swelling to the point of decrease in red cell deformability. Rat erythrocytes, on the other hand, are much smaller initially; consequently, an increase in cell volume of similar magnitude as in human cells will cause a proportionally larger change in the cell's surface area to volume ratio. It appears from our results that at a flunarizine concentration of 50 mg 1', the rat RBC's have swollen beyond optimal geometric proportions to a state which is no more deformable than the dense condition in a hypoxic environment. The morphological correlation is that the rat cells go beyond stomatocytic to more overtly spherical shape, a less deformable geometry. Fenton and Sutherland (1992) have recently reported intertumoural differences in changes in oxygen delivery caused by flunarizine. Doses of flunarizine (5 mg kg-1) similar in magnitude to the lower concentrations tested in our experiments substantially improved oxygen delivery in KHT sarcomas rather than in RIF-1 tumours implanted subcutaneously in mice. Notably, the KHT tumours are more hypoxic initially than the RIF-1, as demonstrated in their control tumours by a lower percentage of blood vessels with at least 10% hemoglobin saturation. These results are entirely consistent with the mechanism of action demonstrated in our experiments. Flunarizine is unlikely to improve upon the regional blood flow within a tumour unless there is a reason (e.g. severe hypoxia) why the red blood cells might be less deformable locally within that region.
In summary, the results reported herein support the idea that the milieu of the hypoxic centres of solid tumours can produce loss of deformability of red blood cells. The drug flunarizine has activity in these circumstances which is characterised by stomatocytogenic changes in red cell morphology, a shift toward lower proportions of the less deformable high density (>1.105 g ml-') red blood cells, and a consequent reduction in the viscosity of bulk suspensions of RBC's. Combined with the available data in animal models documenting enhanced radiosensitivity in vivo with flunarizine, this explanation of the mechanism of activity has encouraged us to pursue implementing the drug within the context of an investigational protocol in human cancer patients.
